Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 182

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 182
---
, $30,000 and $87,000 was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively. We are recognizing the $50.0 million upfront payment under the Roche Agreement utilizing an input method of costs incurred over total estimated costs to be incurred. At each reporting period, we update our total estimated collaboration costs, and any resulting adjustments are recorded on a cumulative basis which would affect revenue and deferred revenue in the period of adjustment. We believe the input methodology represents the most appropriate measure of progress towards satisfaction of the identified performance obligations.For contracts with customers including collaboration partners which are within the scope of ASU 2014-09 – Revenue from Contracts with Customers (Topic 606), the aggregate amount of the transaction price allocated to remaining performance obligations as of December 31, 2024 was $25.6 million, of which $21.8 million is reported as deferred revenues. The $25.6 million is expected to be substantially converted to revenue by December 2026.Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands): 

        December 31, 2024

        December 31, 2023

        Accounts receivable, net - beginning of the year (1)
         
        $
        676

        $
        297

        Accounts receivable, net - end of the period (1)
         
        $
        638

        $
        676

        Contract liabilities (1)

        Deferred revenues - beginning of the year
         
        $
        29,501

        $
        37,146

        Deferred revenues - end of the period (2)
         
        $
        21,821

        $
        29,501

       (1)Excludes grants receivable which are outside the scope of ASU 2014-09.(2)Deferred revenue related to the Roche Agreement was $20.6 million as of December 31, 2024.

113

The following table presents amounts under our collaboration agreements included in the transaction price (i.e., cumulative amounts triggered or probable) as of December 31, 2024 (in thousands): 

        Upfront(1)

        Development(2)

        Reimbursements(3)

        Total

        Collaboration partner and agreement date:

        ITI (April 2021)(4)